T1	Participants 58 97	liver function with fewer side effects.
T2	Participants 379 463	subjects with normal (n = 5) and severely impaired liver function (n = 7) (study I).
T3	Participants 793 907	15 individuals with normal liver function and 45 patients with cirrhosis (15 Child A, 15 Child B, and 15 Child C).
